Polypeptide Lipid-Engineered PEG-Free LNPs for Targeted Delivery of mRNA Vaccines

  • Harnessing PEG-free LNPs deliver mRNA vaccine to lymph nodes with minimal accumulation in the liver
  • Achieving no anti-polypeptide lipid antibody response after repeated dosing
  • Eliciting stronger and more durable immune response with PEG-free LNPs than PEGylated ALC LNPs